Download Image
    
Share
  
Post
Olokizumab for COVID-19
1 study with 248 patients
Hospital Icon Control
Hospital Icon Olokizumab Serious Outcome Risk
COVID-19 Olokizumab studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -50% Mortality -50% RCTs -50% Late -50% Favorsolokizumab Favorscontrol
Apr 1
2023
 Samsonov et al., NCT05187793 A Multicenter, Open-label, Randomized Study of the Efficacy and Safety of Artlegia (INN: Olokizumab) New Dosing Regimen in Patients With Coronavirus Infection (COVID-19) With Signs of Hyperinflammation
198 patient olokizumab late treatment RCT with results not reported over 2 years after completion.
Aug 29
2022
 Samsonov et al., NCT05196477 Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
3,087 patient olokizumab late treatment study with results not reported over 3 years after completion.
Jan 24
2022
 Samsonov et al., NCT04380519 An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)
50% higher mortality (p=0.6) and 30% greater improvement (p=0.21). RCT 248 hospitalized patients showing no significant differences with olokuzimab.